Printer Friendly

Diabetes Devices And Drugs Market 2022 Emerging Trends.

[UKPRwire, Mon Nov 27 2017] The Latest Comprehensive Industry research study titled, Diabetes Devices And Drugs Market by Products, Application - Global Industry Analysis and Forecast To 2022 published by Crystal Market Research. Diabetes occurs either when the pancreas does not produce enough insulin or when the body cannot effectively use the insulin. Symptoms associated with diabetes are frequent urination, blurred vision, increased thirst, rapid weight loss, numbness or tingling sensation in hands or feet and increased hunger. Factors which increase the risk of diabetes are ethnicity, family history, unhealthy diet, physical inactivity and smoking. Diabetes can damage the heart, eyes, blood vessels, kidneys, and nerves which may lead to disability and premature death. There are three types of diabetes, namely, type 1, type 2 and gestational diabetes. Type 1 diabetes can cause due to complex interaction between genes and environmental factors. The most common risk factors for type 2 diabetes are overweight and obesity. However, gestational diabetes develops only during pregnancy. Continuous blood glucose monitoring devices continuously monitors the blood sugar level and displays the data on the monitor. Flash glucose monitors are also used to monitor blood glucose. The monitor shows reading only after scanning its sensor. The insulin pump is a computerized device that helps in controlling diabetes. This pump releases insulin through a catheter into the body. The user can adjust the dose of insulin to be delivered by this pump. Anti diabetic drugs are used for controlling diabetes. These medicines help to control and stabilize the blood glucose level. In patients with type 1 diabetes, insulin is used, whereas in patients with type 2 diabetes, sulfonylurea, biguanides, meglitinides, dipeptidyl-peptidase-4 (DPP-4) inhibitors, alpha-glucosidase inhibitors, sodium glucose cotransporter 2 inhibitors (SGLT2), and glucagon-like peptide-1 (GLP-1) agonist are used. In type 1 diabetes, the insulin used is created by growing insulin proteins within E-coli bacteria in laboratory. The analog insulin is available into various forms. One of the forms is long acting analog insulin. The long acting analog insulin stays in the body for 24 hours, whereas the intermediate acting analog insulin stays in the body for 16 to 24 hours. Another form of insulin is rapid acting analog insulin. Rapid acting insulin stays the body for 3 to 5 hours. On the other hand, short acting analog stays in the body for 6 to 8 hours. Further, premixed analog insulin is also a form of insulin which is used in diabetes. It is made by combining rapid acting and long acting insulin in a ratio. However, in type 2 diabetes patients, sulfonylurea are used. Sulfonylurea stimulate the insulin production in the pancreas. Moreover, sulfonylurea help in increasing the amount of insulin which is produced by the pancreas. Thiazolidinediones is another class of anti diabetic drugs. Thiazolidinediones reduce insulin resistance in fat and muscles. They also lower glucose production by the liver. Meglitinide is another class of anti diabetic drug. Amount of insulin produced by pancreas is increased with the help of meglitinides. Moreover, GLP-I agonists help in maintenance of blood sugar in a target range without leading to low blood sugar or weight gain, whereas alpha glucosidaseinhibitors slow down the digestion of starch thus maintaining the blood sugar level. Browse Complete Report: https://www.crystalmarketresearch.com/report/diabetes-devices-and-drugs-market The major driver for this market is increasing prevalence of diabetes. According to International Diabetes Federation, in 2015, diabetes affected 415 million people worldwide and this number is expected to reach up to 642 million by 2040. Thus, this rapidly rising diabetic population is set to drive the demand for diabetes devices and drugs market. Additionally, increase in prevalence of obesity in geriatric population is set to further drive the market growth. For instance, as per WHO, in 2014, more than 1.9 billion adults, 18 years and older, were overweight. Out of these, over 600 million were obese. Moreover, it states that, in 2014, 41 million children whose age was under 5 were obese or overweight. Further, increasing trend of unhealthy diet will contribute to the growth of diabetes devices and drugs market. However, regulatory framework issues will hamper the growth of diabetic devices and drug market. The major strategy adopted by the major players is product launch to gain market share and to gain competitive edge. For instance, in 2015, Janssen India launched INVOKANA for diabetic patients. INVOKANA is a sodium glucose co-transporter 2 inhibitor. It helps adults to achieve adequate control on diabetes who previously were not able to achieve control on diabetes. Major Market Players: AaAaAeAcy GlaxoSmithKline PLC Aa Abbott Laboratories AaAaAeAcy Takeda Pharmaceutical Company Limited AaAaAeAcy AstraZe AaAaAeAcy Johnson & Johnson Services, Inc. AaAaAeAcy F. Hoffmann La-Roche Ltd. B. Braun Melsungen AG AaAaAeAcy Bayer AG AaAaAeAcy Becton AaAaAeAcy Dickinson and C AaAaAeAcy BoehringerIngelheim International GmbH AaAaAeAcy DexCom, Inc. AaAaAeAcy Eli and Company AaAaAeAcy Lupin Limited AaAaAeAcy Novo Nordisk A/S AaAaAeAcy Medtronic AaAaAeAcy Merck & Co., Inc. AaAaAeAcy Novartis AG AaAaAeAcy Sanofi. Request TOC: https://www.crystalmarketresearch.com/report/diabetes-devices-and-drugs-market#customi Diabetes Devices and Drugs Market Segmentation: By Devices: Insulin Delivery Devices o Insulin Injectors o Insulin Syringes o Insulin Pumps o Insulin Pens Diabetes Monitoring and Diagnostic Devices o Continuous Glucose Monitoring Devices o Analog Glucose Meter o Lancets and Lancing Devices o Glucose Test Strips o Others By Therapy: Non-insulin Injectable Anti-diabetes Drugs o GLP-1 Analogs Oral Anti-diabetes Drugs Class o SGLT-2 Inhibitors o Sulphonylureas o Thiazolidinediones o DPP-4 Inhibitors o Biguanides o Alpha-glucosidaseInhibitors o Meglitinides Insulin o Premixed Insulin Derivatives o Intermediate-acting Insulin Derivatives o Rapid-acting Insulin Derivatives o Short-acting Insulin Derivatives o Long-acting Insulin Derivatives By Region: North America o U.S o Canada o Mexico Europe o Germany o France o UK o Italy o Spain o Rest of Europe Asia-Pacific o Japan o China o Australia o India o South Korea o Rest of Asia-Pacific Rest of the World o Brazil o South Africa o Saudi Arabia o Turkey o United Arab Emirates o Others About Us: Crystal Market Research is a U.S. based market research and business intelligence company. Crystal offers one stop solution for market research, business intelligence, and consulting services to help clients make more informed decisions. It provides both syndicated as well as customized research studies for its customers spread across the globe. The company offers market intelligence reports across a broad range of industries including healthcare, chemicals & materials, technology, automotive, and energy. Contact Us: Judy 304 South Jones Blvd, Suite 1896, Las Vegas NV 89107, United States Toll Free: +1-888-213-4282 Email: sales@crystalmarketresearch.com Blog: blog.crystalmarketresearch.com Website: www.crystalmarketresearch.com

Copyright [c] 2017 UKPRwire Provided by SyndiGate Media Inc. ( Syn
COPYRIGHT 2017 SyndiGate Media Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:UKPRwire
Date:Nov 27, 2017
Words:1097
Previous Article:Pain Management Devices Market 2022 Key Manufacturers Analysis.
Next Article:Stents Market 2022 New Research Study.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters